A Pilot Study of Dronabinol for Adult Patients With Primary Gliomas

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

October 31, 2011

Study Completion Date

April 30, 2012

Conditions
Brain NeoplasmsNauseaVomiting
Interventions
DRUG

Dronabinol

Oral route, 5mg PO 2x daily before and during 2 cycles of chemotherapy,2.5mg PO every night when not on chemotherapy

Trial Locations (1)

27710

Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Solvay Pharmaceuticals

INDUSTRY

lead

Duke University

OTHER